Lexaria Bioscience Corp.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $705.9K
- Net income
- -$11.9M
- Total assets
- $4.2M
- Market cap
- $15.8M
- Gross margin
- 99.6%
- Operating margin
- -1683.0%
- Net margin
- -1687.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $705.9K
- Cost of revenue
- $2.7K
- Gross profit
- $703.2K
- Operating expenses
- $12.6M
- Operating income
- -$11.9M
- Net income
- -$11.9M
- EPS (diluted)
- $-0.66
Balance sheet
- Total assets
- $4.2M
- Current assets
- $3.5M
- Total liabilities
- $1.6M
- Current liabilities
- $1.5M
- Shareholders’ equity
- $2.6M
Cash flow
- Operating cash flow
- -$10.5M
- Investing cash flow
- -$243.0K
- Financing cash flow
- $6.0M
- Net cash flow
- -$4.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $15.8M
- EPS (diluted)
- $-0.66
- Shares outstanding
- 24.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 8, 2006
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $11.9M in FY2025.
- Revenue declined 2% from FY2021 to FY2025.
- Gross margin of 99.6%, net margin -1687.4%.
- Trading 58% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Lexaria Bioscience Corp..
Write a review
News about Lexaria Bioscience Corp.
News & sentiment via Polygon.io
